Put companies on watchlist
Nektar Therapeutics
ISIN: US6402681083
WKN: 165417
Curious about what AI knows about Nektar Therapeutics? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Nektar Therapeutics · ISIN: US6402681083 · PR Newswire (ID: 20241106SF48990)
07 November 2024 12:00AM

Nektar Therapeutics to Participate in Upcoming Investor Conferences


SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences:

  • UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here
  • Piper Sandler 36th Annual Healthcare Conference in New York, NY on Wednesday, December 4, 2024 at 1:00 p.m. Eastern Time / 4:00 p.m. Pacific Time – webcast link here

The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contact:

For Investors:

Vivian Wu

Nektar Therapeutics

628-895-0661

For Media:

Madelin Hawtin

LifeSci Communications

603-714-2638

mhawtin@lifescicomms.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-upcoming-investor-conferences-302297943.html

SOURCE Nektar Therapeutics

Visual performance / price development - Nektar Therapeutics
Smart analysis and research tools can be found here.
MIC: XNAS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942